Sierra Oncology, Inc. Sustainability Profile
Sierra Oncology, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 2003, the company has made substantial strides in developing innovative therapies for patients with cancer, particularly focusing on rare and underserved malignancies. Sierra Oncology is best known for its lead product, momelotinib, a unique treatment designed to address myelofibrosis and other related conditions. This targeted therapy stands out for its ability to alleviate symptoms while also addressing the underlying disease mechanisms. With a commitment to advancing cancer care, Sierra Oncology has established a strong market position, recognised for its dedication to research and development. The company continues to achieve notable milestones, contributing to the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does Sierra Oncology, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sierra Oncology, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sierra Oncology, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. However, the company is part of a corporate family relationship with GSK plc, from which it inherits various climate commitments and initiatives. Sierra Oncology's climate commitments are aligned with those of GSK plc, which has established significant reduction targets and initiatives. These include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all aimed at reducing carbon emissions and promoting sustainability. The specific targets and achievements of these initiatives are cascaded from GSK plc, reflecting a commitment to addressing climate change at a corporate level. While Sierra Oncology does not have its own emissions data, it is positioned within a framework that prioritises climate action and sustainability, guided by the overarching goals set by GSK plc. This relationship underscores the importance of corporate responsibility in mitigating climate impacts within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,040,928,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 788,149,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,630,521,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
How Carbon Intensive is Sierra Oncology, Inc.'s Industry?
How Carbon Intensive is Sierra Oncology, Inc.'s Location?
Sierra Oncology, Inc.'s Scope 3 Categories Breakdown
Sierra Oncology, Inc.'s Scope 3 emissions, which decreased by 0% last year and decreased by approximately 46% since 2013, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Use of Sold Products" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Sierra Oncology, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sierra Oncology, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
